All patients were ranked in New York Heart Association class 2 or better.
按照纽约心脏病协会分级所有的患者被分级为2级或更好。
The primary end point was a composite of death, myocardial reinfarction, or New York Heart Association (NYHA) class IV heart failure.
主要结果为对死亡，心肌梗死再复发或者纽约心脏协会（NYHA）分级的IV级心脏衰竭的综合评价。
Primary efficacy measures were the 6-minute walking distance (6mwd) test, change in New York Heart Association functional class and several standard dyspnoea rating scales.
主要有效评估是6分钟步行距离(6mwd)测试，纽约心脏协会功能级别改变以及几种标准呼吸困难等级评分。
Adverse outcomes, defined as death, sustained ventricular tachycardia (VT), and increase in New York Heart Association functional class to grade II or IV, occurred in 21% of patients.
确定死亡、持续性室性心动过速、纽约心功能分级增加到II或IV级等负性结果发生率为21%。
Adverse outcomes, defined as death, sustained ventricular tachycardia (VT), and increase in New York Heart Association functional class to grade II or IV, occurred in 21% of patients.
确定死亡、持续性室性心动过速、纽约心功能分级增加到II或IV级等负性结果发生率为21%。
应用推荐